Suspension of trading
Exscientia plc Stock
Stocks
EXAI
US30223G1022
Biotechnology & Medical Research
|
Delayed
Nasdaq
08:00:00 20/11/24 am AEDT
|
5-day change | 1st Jan Change | ||
| 4.840 USD | +3.20% |
|
-.--% | - |
| 21/11/24 | Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index | CI |
| 21/11/24 | Recursion Pharmaceuticals, Exscientia Complete Business Combination | MT |
| Market Cap | 500M 681M 584M 546M 938M 65.18B 950M 6.45B 2.52B 32.74B 2.56B 2.5B 108B | P/E 2022 |
-4.55x | P/E 2023 | -4.28x |
|---|---|---|---|---|---|
| Enterprise Value | 156M 212M 182M 170M 292M 20.31B 296M 2.01B 784M 10.2B 797M 780M 33.74B | EV / Sales 2022 |
1.9x | EV / Sales 2023 | 14.2x |
| Free-Float |
36.87% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +3.20% |
| 3 years | 3.8 |  | 7.91 |
| 5 years | 3.8 | | 30.38 |
| 10 years | 3.8 | | 30.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 61 | 06/06/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/05/2022 | |
John Overington
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Mario Polywka
BRD | Director/Board Member | 63 | 28/09/2017 |
Robert Ghenchev
BRD | Director/Board Member | 43 | 01/05/2020 |
Elizabeth Crain
CHM | Chairman | 61 | 12/02/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.20% | -.--% | -.--% | -28.72% | 633M | |
| -0.68% | +3.95% | +2.79% | +23.31% | 51.61B | |
| -1.59% | -2.70% | +478.30% | +548.27% | 44.89B | |
| +0.34% | +8.06% | +38.65% | +20.96% | 42.77B | |
| -2.27% | +1.11% | +18.76% | +84.30% | 42.58B | |
| -0.93% | -4.33% | +16.18% | +55.82% | 31.82B | |
| -0.23% | +3.75% | +32.71% | +145.03% | 17.33B | |
| -1.69% | +0.53% | - | - | 16.63B | |
| +0.52% | +4.60% | +9.71% | +30.80% | 14.76B | |
| +0.22% | +3.13% | +80.12% | +48.83% | 14.09B | |
| Average | -0.30% | +3.99% | +75.25% | +103.18% | 27.71B | |
| Weighted average by Cap. | -0.83% | +4.71% | +101.44% | +137.12% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 27.22M 37.1M 31.78M 29.74M 51.09M 3.55B 51.76M 351M 137M 1.78B 139M 136M 5.9B | 20.08M 27.37M 23.44M 21.94M 37.68M 2.62B 38.18M 259M 101M 1.32B 103M 101M 4.35B |
| Net income | -119M -162M -139M -130M -223M -15.48B -226M -1.53B -598M -7.78B -608M -594M -25.73B | -146M -199M -170M -159M -274M -19.04B -278M -1.88B -735M -9.56B -747M -731M -31.63B |
| Net Debt | -492M -670M -574M -537M -923M -64.15B -935M -6.35B -2.48B -32.23B -2.52B -2.46B -107B | -344M -469M -402M -376M -646M -44.88B -654M -4.44B -1.73B -22.54B -1.76B -1.72B -74.57B |
Employees
483
- Stock Market
- Stocks
- EXAI Stock
Select your edition
All financial news and data tailored to specific country editions
